Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.59 |
| ▸ | ESRRA | P11474 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3487630 | 0.91 | PPARG (0.65) | PPARGESRRA | |
| SCHEMBL3487449 | 0.89 | PPARG (0.59) | PPARGESRRANPC1RAB9A | |
| SCHEMBL3486865 | 0.89 | PPARG (0.63) | PPARGESRRA | |
| SCHEMBL3487262 | 0.89 | PPARG (0.52) | PPARGESRRA | |
| SCHEMBL3487370 | 0.88 | PPARG (0.60) | PPARGNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8478530 | 0.88 | PPARG (0.64) | PPARGESRRA | |
| SCHEMBL3487187 | 0.87 | PPARG (0.54) | PPARG | |
| SCHEMBL3486578 | 0.86 | PPARG (0.49) | PPARGESRRA | |
| SCHEMBL3486590 | 0.86 | PPARG (0.47) | PPARG | |
| SCHEMBL3487259 | 0.85 | PPARG (0.54) | PPARGESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138484-B1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-20130035337-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-02-07 | — | — | US | disclosed |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2138484-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035337-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | PPARG 1/4885ESRRA 339/4885NPC1 147/4885 |
| US-20100048564-A1 | FUSED BICYCLIC HETEROARYL DERIVATIVE | PPARG, GPR119, PPARA | PPARG 1/4885ESRRA 339/4885NPC1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.